The remarkable success in treatment of Hodgkin's Lymphoma (HL) creates the challenge of long-term management of patients who are, unfortunately, at risk for premature death. Despite excellent control of the disease, long-term outcome remains inferior to that of the general population. Excess mortality is, in general, due to HL itself during the first 5-10 years after diagnosis, but treatment-related complications affect survival 25-30 years after therapy. HL patients should be followed life long, and the schedule and the nature of this surveillance should be tailored to the temporal patterns of complications (Figure 76.1). While detection of recurrence may be most important during the first 5 years, detection and prevention of cardiac, thyroid, and pulmonary disease should be ongoing and screening for secondary malignancies should be employed when possible.

0 0

Post a comment